Transforming patient outcome of pulmonary aspergillosis with better and faster diagnosis and therapy

Impact: Health and wellbeing, Economic

Narrative

The airborne fungus Aspergillus causes life-threatening invasive aspergillosis and chronic pulmonary aspergillosis ((CPA), five-year mortality >50%) and exacerbates asthma. Our world-leading aspergillosis research has: 1) improved diagnostics, aiding earlier effective treatment; 2) led to new treatments through multiple drug studies; 3) improved patient survival and quality of life. Notably, Voriconazole results in 13% improved survival in invasive aspergillosis and has been used to treat millions of patients (peak annual sales over USD750,000,000). Since August 2013, the National Aspergillosis Centre (NAC), led by Denning, has treated >800 new patients, with >9,900 outpatient follow-up attendees. Manchester publications are embodied in European and US treatment guidelines for invasive aspergillosis and CPA.
Impact date1 Aug 2013 → 31 Jul 2020
Category of impactHealth and wellbeing, Economic
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Lydia Becker Institute

Documents & Links

Related content